Ayala Pharmaceuticals, Inc. Contracts & Agreements
31 Contracts & Agreements
- Business Finance (11 contracts)
- Business Operations (3)
- Human Resources (6)
- Intellectual Property (3)
- Mergers & Acquisitions (1)
- Real Estate (1)
- Uncategorized (6)
- Description of Securities (Filed With SEC on March 31, 2023)
- Agreement and Plan of Merger, dated as of October 18, 2022, by and among Advaxis, Inc., Doe Merger Sub, Inc., and Ayala Pharmaceuticals, Inc (Filed With SEC on October 19, 2022)
- Voting and Support Agreement, dated as of October 18, 2022, by and between Advaxis, Inc. and Israel Biotech Fund I, L.P (Filed With SEC on October 19, 2022)
- Voting and Support Agreement, dated as of October 18, 2022, by and between Advaxis, Inc. and aMoon Growth Fund Limited Partnership (Filed With SEC on October 19, 2022)
- Letter Agreement, dated as of October 18, 2022, by and between Ayala-Oncology Israel Ltd. and Roni Mamluk (Filed With SEC on October 19, 2022)
- Letter Agreement, dated as of October 18, 2022, by and between Ayala-Oncology Israel Ltd. and Yossi Maimon (Filed With SEC on October 19, 2022)
- Letter Agreement, dated as of October 18, 2022, by and between Ayala Pharmaceuticals, Inc. and Gary Gordon (Filed With SEC on October 19, 2022)
- Amendment No. 2 to Amended and Restated Investors Rights Agreement, dated as of June 4, 2021 (Filed With SEC on August 15, 2022)
- Form of Underwriting Agreement (Filed With SEC on July 18, 2022)
- Form of Common Stock Warrant (Filed With SEC on July 18, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on July 18, 2022)
- Description of Securities (Filed With SEC on March 28, 2022)
- Description of Securities (Filed With SEC on March 24, 2021)
- Form of Common Warrant (Filed With SEC on February 22, 2021)
- Form of Pre-Funded Warrant (Filed With SEC on February 22, 2021)
- Securities Purchase Agreement, dated February 19, 2021, by and among Ayala Pharmaceuticals, Inc. and the Investors named therein (Filed With SEC on February 22, 2021)
- Amended and Restated Investors Rights Agreement, as amended (Filed With SEC on May 4, 2020)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on May 4, 2020)
- Amended 2017 Stock Incentive Plan and form of agreements thereunder (Filed With SEC on May 4, 2020)
- Non-Employee Director Compensation Program (Filed With SEC on May 4, 2020)
- Form of Indemnification Agreement for Directors and Officers (Filed With SEC on May 4, 2020)
- Employment Agreement, dated July 24, 2019, between the Registrant and Gary Gordon M.D., Ph.D., as amended (Filed With SEC on May 4, 2020)
- License Agreement, dated November 29, 2017, between the Registrant and Bristol-Myers Squibb Company, as amended (Filed With SEC on May 4, 2020)
- Form of Underwriting Agreement (Filed With SEC on March 6, 2020)
- Amended and Restated Investors Rights Agreement (Filed With SEC on March 6, 2020)
- Lease Agreement, dated January 24, 2019, between Ayala-Oncology Israel Ltd. and Ogen Real Estate Maniv Ltd (Filed With SEC on March 6, 2020)
- Employment Agreement, dated December 26, 2017, between Ayala-Oncology Israel Ltd. and Roni Mamluk, Ph.D., as amended (Filed With SEC on March 6, 2020)
- Employment Agreement, dated March 15, 2019, between Ayala-Oncology Israel Ltd. and Yossi Maimon, CPA, M.B.A., as amended (Filed With SEC on March 6, 2020)
- Employment Agreement, dated July 24, 2019, between the Registrant and Gary Gordon M.D., Ph.D (Filed With SEC on March 6, 2020)
- License Agreement, dated November 29, 2017, between the Registrant and Bristol-Myers Squibb Company (Filed With SEC on March 6, 2020)
- Evaluation, Option and License Agreement, dated December 19, 2018, between the Registrant and Novartis International Pharmaceutical Limited (Filed With SEC on March 6, 2020)
